Regulation, compounding decisions, GLP-1 trial data, and the compounds the research world is watching — tracked and summarized in plain English. Last updated: July 01, 2026.
Curated headlines with context. Everything here is for research and educational purposes only — not medical or investment advice.
The Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to evaluate whether several of the most-discussed research peptides meet the criteria for the 503A Bulk Drug Substances list — a decision the whole category is watching.
The first diabetes-specific Phase 3 readout for the triple-agonist retatrutide showed A1C reductions up to 2.0% and weight reductions up to ~16.8% at 40 weeks, with a large share of participants reaching normal A1C.
The pivotal obesity trial (2,339 patients, 80 weeks) reported 28.3% average weight loss at 12mg, with 45.3% of participants losing at least 30% of body weight — among the largest reductions recorded in a trial.
Following withdrawal of their nominations, the FDA removed BPC-157 and TB-500 from Category 2 — but did not move them to Category 1, leaving them in a regulatory gray zone pending the July committee review.
HHS signaled that roughly 14 of 19 restricted peptides are expected to move back toward Category 1 status, potentially restoring a compounding pathway under prescription — though the formal FDA list is still pending.
Semaglutide, tirzepatide and retatrutide continue to dominate research-peptide search demand in 2026, with the triple-agonist class driving the fastest-rising interest.